(NEOG) Neogen - Overview
Stock: Diagnostics, Kits, Reagents, Instruments, Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 52.9% |
| Relative Tail Risk | -13.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | -6.01 |
| Character TTM | |
|---|---|
| Beta | -0.145 |
| Beta Downside | 0.598 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.59% |
| CAGR/Max DD | -0.24 |
Description: NEOG Neogen January 19, 2026
Neogen Corp. (NASDAQ: NEOG) designs, manufactures, and markets diagnostic and safety solutions for the food and animal sectors, operating through two distinct segments: Food Safety and Animal Safety. The company, founded in 1981 and based in Lansing, Michigan, serves a global customer base that includes food processors, veterinarians, livestock producers, and research institutions.
The Food Safety segment provides a broad portfolio of test kits, software, and laboratory services that detect pathogens, toxins, allergens, drug and pesticide residues, and other contaminants in human food, animal feed, and water. Its addressable market is expanding as regulatory agencies (e.g., FDA, EU) tighten testing requirements; the segment generated roughly $190 million in revenue in FY 2023, representing a 10% year-over-year increase driven by higher demand for rapid sanitation tests and digital data-management platforms.
The Animal Safety segment offers immunoassay reagents, veterinary instruments, nutritional supplements, pest-control products, and genomics services such as DNA genotyping for livestock and companion animals. FY 2023 sales were about $80 million, with operating margins improving to 15% after the 2022 acquisition of a genomics-focused startup that broadened its high-growth livestock-trait analysis capability.
For analysts seeking a data-driven view of NEOG’s valuation dynamics, a quick look at ValueRay’s quantitative model can help surface hidden risk factors and upside catalysts.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -602.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.81 > 1.0 |
| NWC/Revenue: 48.56% < 20% (prev 45.88%; Δ 2.69% < -1%) |
| CFO/TA 0.02 > 3% & CFO 66.2m > Net Income -602.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.4m) vs 12m ago 0.27% < -2% |
| Gross Margin: 38.05% > 18% (prev 0.44%; Δ 3761 % > 0.5%) |
| Asset Turnover: 23.75% > 50% (prev 22.54%; Δ 1.21% > 0%) |
| Interest Coverage Ratio: -8.33 > 6 (EBITDA TTM -433.7m / Interest Expense TTM 66.2m) |
Altman Z'' -1.09
| A: 0.13 (Total Current Assets 574.6m - Total Current Liabilities 147.1m) / Total Assets 3.36b |
| B: -0.15 (Retained Earnings -516.0m / Total Assets 3.36b) |
| C: -0.15 (EBIT TTM -551.3m / Avg Total Assets 3.71b) |
| D: -0.40 (Book Value of Equity -506.8m / Total Liabilities 1.26b) |
| Altman-Z'' Score: -1.09 = CCC |
Beneish M -3.28
| DSRI: 0.84 (Receivables 132.0m/164.1m, Revenue 880.3m/913.8m) |
| GMI: 1.17 (GM 38.05% / 44.35%) |
| AQI: 0.93 (AQ_t 0.73 / AQ_t-1 0.78) |
| SGI: 0.96 (Revenue 880.3m / 913.8m) |
| TATA: -0.20 (NI -602.7m - CFO 66.2m) / TA 3.36b) |
| Beneish M-Score: -3.28 (Cap -4..+1) = AA |
What is the price of NEOG shares?
Over the past week, the price has changed by +1.84%, over one month by +45.18%, over three months by +74.50% and over the past year by -0.94%.
Is NEOG a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NEOG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.7 | 10.7% |
| Analysts Target Price | 11.7 | 10.7% |
| ValueRay Target Price | 10.4 | -1.6% |
NEOG Fundamental Data Overview February 02, 2026
P/S = 2.5254
P/B = 1.0584
P/EG = 0.6575
Revenue TTM = 880.3m USD
EBIT TTM = -551.3m USD
EBITDA TTM = -433.7m USD
Long Term Debt = 792.9m USD (from longTermDebt, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last fiscal year)
Debt = 792.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 647.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.87b USD (2.22b + Debt 792.9m - CCE 145.3m)
Interest Coverage Ratio = -8.33 (Ebit TTM -551.3m / Interest Expense TTM 66.2m)
EV/FCF = 166.9x (Enterprise Value 2.87b / FCF TTM 17.2m)
FCF Yield = 0.60% (FCF TTM 17.2m / Enterprise Value 2.87b)
FCF Margin = 1.95% (FCF TTM 17.2m / Revenue TTM 880.3m)
Net Margin = -68.47% (Net Income TTM -602.7m / Revenue TTM 880.3m)
Gross Margin = 38.05% ((Revenue TTM 880.3m - Cost of Revenue TTM 545.4m) / Revenue TTM)
Gross Margin QoQ = 47.48% (prev 34.40%)
Tobins Q-Ratio = 0.85 (Enterprise Value 2.87b / Total Assets 3.36b)
Interest Expense / Debt = 1.87% (Interest Expense 14.8m / Debt 792.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -435.5m (EBIT -551.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.91 (Total Current Assets 574.6m / Total Current Liabilities 147.1m)
Debt / Equity = 0.38 (Debt 792.9m / totalStockholderEquity, last quarter 2.10b)
Debt / EBITDA = -1.49 (negative EBITDA) (Net Debt 647.6m / EBITDA -433.7m)
Debt / FCF = 37.66 (Net Debt 647.6m / FCF TTM 17.2m)
Total Stockholder Equity = 2.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.26% (Net Income -602.7m / Total Assets 3.36b)
RoE = -26.92% (Net Income TTM -602.7m / Total Stockholder Equity 2.24b)
RoCE = -18.19% (EBIT -551.3m / Capital Employed (Equity 2.24b + L.T.Debt 792.9m))
RoIC = -14.14% (negative operating profit) (NOPAT -435.5m / Invested Capital 3.08b)
WACC = 4.35% (E(2.22b)/V(3.02b) * Re(5.38%) + D(792.9m)/V(3.02b) * Rd(1.87%) * (1-Tc(0.21)))
Discount Rate = 5.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.23%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈17.2m ; Y1≈11.3m ; Y5≈5.15m
Fair Price DCF = N/A (negative equity: EV 164.1m - Net Debt 647.6m = -483.5m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 19.69 | EPS CAGR: 20.30% | SUE: 1.55 | # QB: 3
Revenue Correlation: 62.15 | Revenue CAGR: 16.13% | SUE: 3.45 | # QB: 2
EPS current Year (2026-05-31): EPS=0.36 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+8.1% | Growth Revenue=-4.9%
EPS next Year (2027-05-31): EPS=0.32 | Chg30d=-0.037 | Revisions Net=-1 | Growth EPS=-9.3% | Growth Revenue=+1.7%